Astellas Pharma provides a portfolio of urology medicines including a leading treatment for overactive bladder (OAB) and for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).

OAB is a serious urological condition that affects nearly 1 in 5 men and women across Europe, disrupting normal life because of the sudden and compelling need to go to the toilet during the day or the night. It is a significantly under diagnosed condition that may result in incontinence, and meeting this unmet medical need is a serious focus for Astellas both with its current portfolio and its ongoing research and development efforts.

LUTS and BPH are two other serious urological conditions, with BPH affecting more than 50% of men aged 50 years or over and more than 90% of men over the age of 80 years. Like OAB, both conditions are disruptive to normal life causing the frequent and urgent need to go to the toilet, and both are often significantly under diagnosed. Astellas has developed a treatment for LUTS, associated with BPH, which relaxes the bladder neck as well as the prostate urethra and smooth muscle and improves bladder storage to reduce the symptoms of the condition.

As a leading pharmaceutical company, Astellas Pharma continues to pioneer the development of medicines for unmet urological conditions including Overactive Bladder (OAB), lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).

To learn more on OAB please access link: www.oab.ie